| Closing Price ($) | Shares Out (MM) | Market Cap ($MM) |
| $1.49 | 23 | $34 |
| 10-Q | 2019-09-30 | Quarter: 2019-09-30 |
| S-1 | 2019-07-31 | Public Filing |
| 10-Q | 2019-06-30 | Quarter: 2019-06-30 |
| 10-Q | 2019-03-31 | Quarter: 2019-03-31 |
| 10-K | 2018-12-31 | Annual: 2018-12-31 |
| 10-Q | 2018-09-30 | Quarter: 2018-09-30 |
| 10-Q | 2018-03-31 | Quarter: 2018-03-31 |
| 10-Q | 2018-03-31 | Quarter: 2018-03-31 |
| 10-K | 2017-12-31 | Annual: 2017-12-31 |
| 10-Q | 2017-09-30 | Quarter: 2017-09-30 |
| 10-Q | 2017-06-30 | Quarter: 2017-06-30 |
| 10-Q | 2017-03-31 | Quarter: 2017-03-31 |
| 10-K | 2016-12-31 | Annual: 2016-12-31 |
| 8-K | 2019-11-18 | Other Events |
| 8-K | 2019-11-14 | Earnings, Exhibits |
| 8-K | 2019-09-16 | Regulation FD, Exhibits |
| 8-K | 2019-08-09 | Earnings, Exhibits |
| 8-K | 2019-08-06 | Other Events, Exhibits |
| 8-K | 2019-07-10 | Enter Agreement, Sale of Shares, Other Events, Exhibits |
| 8-K | 2019-06-11 | Shareholder Vote |
| 8-K | 2019-05-17 | Other Events |
| 8-K | 2019-05-15 | Earnings, Exhibits |
| 8-K | 2019-04-01 | Earnings, Exhibits |
| 8-K | 2019-03-18 | Other Events, Exhibits |
| 8-K | 2019-02-05 | Other Events, Exhibits |
| 8-K | 2019-02-01 | Enter Agreement, Exhibits |
| 8-K | 2019-02-01 | Other Events, Exhibits |
| 8-K | 2019-01-31 | Other Events, Exhibits |
| 8-K | 2019-01-24 | |
| 8-K | 2019-01-14 | Other Events, Exhibits |
| 8-K | 2018-12-14 | Other Events, Exhibits |
| 8-K | 2018-11-13 | Enter Agreement, Exhibits |
| 8-K | 2018-10-21 | Other Events, Exhibits |
| 8-K | 2018-09-07 | Enter Agreement, Exhibits |
| 8-K | 2018-07-23 | Other Events, Exhibits |
| 8-K | 2018-05-03 | Shareholder Vote |
| 8-K | 2018-04-16 | Other Events, Exhibits |
| 8-K | 2018-03-27 | Other Events, Exhibits |
| 8-K | 2018-03-23 | Enter Agreement, Exhibits |
| 8-K | 2018-03-22 | Other Events, Exhibits |
| 8-K | 2018-03-14 | Other Events, Exhibits |
| 8-K | 2018-01-12 | Enter Agreement, Shareholder Rights, Shareholder Vote, Exhibits |
| Comps ($'000 TTM) | Market Cap | Assets | Liabilities | Revenue | Gross Profit | Net Income | EBITDA | EV |
|---|---|---|---|---|---|---|---|---|
| Vascular Biogenics (VBLT) | 31,934 | 60,678 | 7,585 | 0 | 0 | 0 | 0 | 31,934 |
| Actinium Pharmaceuticals (ATNM) | 40,508 | 21,819 | 6,118 | 0 | 0 | -23,165 | -22,956 | 20,808 |
| Bellerophon Therapeutics (BLPH) | 42,722 | 20,578 | 9,116 | 0 | 0 | 5,289 | 3,488 | 25,522 |
| Aclaris (ACRS) | 210,933 | 217,239 | 80,009 | 19,616 | 9,434 | -158,732 | -152,933 | 125,340 |
| AEterna Zentaris (AEZS) | 48,829 | 25,011 | 23,104 | 0 | 0 | 0 | 0 | 45,328 |
| Eyenovia (EYEN) | 52,676 | 10,036 | 2,418 | 0 | 0 | -21,770 | -21,758 | 43,436 |
| Zosano Pharma (ZSAN) | 58,309 | 45,787 | 26,780 | 0 | 0 | -37,102 | -36,217 | 40,609 |
| Celsion (CLSN) | 38,224 | 43,587 | 24,755 | 500 | 0 | -7,448 | -6,903 | 42,211 |
| Pernix Therapeutics Holdings (PTX) | 12,702 | 274,770 | 447,052 | 69,680 | 19,178 | -76,365 | -44,352 | 352,585 |
| Proteostasis Therapeutics (PTI) | 48,033 | 105,749 | 23,764 | 0 | 0 | -69,764 | -68,376 | -39,967 |
| Leap Therapeutics (LPTX) | 37,866 | 20,137 | 9,198 | 0 | 0 | -22,121 | -22,100 | 22,119 |
| Aptevo Therapeutics (APVO) | 39,687 | 66,127 | 39,928 | 26,552 | 4,550 | -52,040 | -49,681 | 30,790 |
| Zafgen (ZFGN) | 47,778 | 103,884 | 31,745 | 0 | 0 | -54,878 | -52,926 | -25,741 |
| Bio-Path (BPTH) | 36,661 | 19,319 | 1,406 | 0 | 0 | -8,958 | -8,859 | 19,555 |
| Sierra Oncology (SRRA) | 43,319 | 84,175 | 13,704 | 0 | 0 | -57,760 | -57,561 | -30,812 |
| Innovate Biopharmaceuticals (INNT) | 39,831 | 14,640 | 9,633 | 0 | 0 | -12,714 | -10,259 | 30,538 |
| Alimera Sciences (ALIM) | 29,110 | 50,242 | 53,924 | 49,996 | 44,932 | -12,499 | -4,567 | 55,209 |
| DiaMedica Therapeutics (DMAC) | 55,952 | 12,797 | 1,095 | 0 | 0 | -5,721 | -5,704 | 52,978 |
| Vistagen Therapeutics (VTGN) | 12,947 | 11,322 | 0 | 0 | -26,585 | -26,474 | -8,051 | |
| Aerpio Pharmaceuticals (ARPO) | 36,529 | 49,600 | 3,884 | 18,824 | 0 | -11,158 | -11,158 | -11,628 |
| Balance Sheet ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Cash | 23,800 | 17,171 | 14,203 | 25,737 | 35,376 | 30,481 | 23,249 | 16,284 | 21,709 | 15,747 |
| Accounts Receivable | ||||||||||
| Inventory | ||||||||||
| PP&E | 159 | 160 | 148 | 208 | 123 | 111 | 98 | 208 | 74 | 161 |
| Assets | 28,779 | 22,726 | 17,579 | 29,062 | 38,686 | 34,407 | 27,126 | 19,074 | 26,083 | 20,137 |
| Accounts Payable | 2,793 | 3,088 | 2,598 | 2,622 | 4,130 | 4,766 | 4,149 | 3,579 | 3,298 | 5,325 |
| Long-Term Debt | ||||||||||
| Liabilities | 4,612 | 4,375 | 5,994 | 17,945 | 22,558 | 22,272 | 20,498 | 9,899 | 9,019 | 9,198 |
| Stockholders' Equity | 24,167 | 18,351 | 11,585 | 11,117 | 16,128 | 12,135 | 6,628 | 9,175 | 17,064 | 10,939 |
| Income Statement ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Revenue | ||||||||||
| Cost of Revenue | ||||||||||
| Gross Profit | ||||||||||
| R&D | 6,404 | 4,881 | 6,802 | 4,416 | 4,231 | 4,234 | 6,457 | 6,908 | 6,790 | 6,136 |
| SG&A | ||||||||||
| Tax | ||||||||||
| Net Income | -9,414 | -6,905 | -6,815 | -6,593 | -10,622 | -7,364 | -6,632 | 1,480 | -8,603 | -8,366 |
| Cash Flow ($'000) | 2017-03-31 | 2017-06-30 | 2017-09-30 | 2017-12-31 | 2018-03-31 | 2018-06-30 | 2018-09-30 | 2018-12-31 | 2019-03-31 | 2019-06-30 |
| Cash Operating | -2,357 | -6,369 | -5,478 | -6,053 | -7,452 | -7,050 | -6,868 | -7,183 | ||
| Cash Investing | 2 | 0 | ||||||||
| Cash Financing | 0 | 17,895 | 15,005 | 1,008 | -67 | -40 | 12,322 | 1,260 |